Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer

Trial Profile

Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs EMD 640744 (Primary) ; Cyclophosphamide
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Immunovaccine
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2016 According to Immunovaccine media release, the company announced additional topline results from phase 1/1b trial of DPX-Survivac in ovarian cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top